Active, not recruitingPhase 3NCT04224493
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Studying Lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Epizyme, Inc.
- Principal Investigator
- Ipsen Medical DirectorIpsen
- Intervention
- Tazemetostat(drug)
- Enrollment
- 555 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2029
Study locations (30)
- Southern Cancer Center, Mobile, Alabama, United States
- Arizona Oncology Associates - Tuscon-Rusadill Road, Tucson, Arizona, United States
- TOI - Clinical Research, Cerritos, California, United States
- UCSF Fresno, Clovis, California, United States
- UC San Diego Health Sciences, La Jolla, California, United States
- UCLA Clinical Research Unit Hematology/Oncology, Santa Monica, California, United States
- Rocky Mountain Cancer Centers (RMCC) - Boulder, Boulder, Colorado, United States
- St. Mary's Hospital and Regional Medical Center - St. Mary's, Grand Junction, Colorado, United States
- Cancer Specialists of North Florida, Fleming Island, Florida, United States
- Florida Cancer Specialists & Research Institute (FCS) - Fort Myers Cancer Center, Fort Myers, Florida, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Florida Cancer Affiliates/Ocala Oncology - Clinic, Ocala, Florida, United States
- BRCR Medical Center, INC, Plantation, Florida, United States
- Florida Cancer Specialists, St. Petersburg, Florida, United States
- Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04224493 on ClinicalTrials.govOther trials for Lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07511426U96-CAR-T-Cells For R/R B-ALLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07316010Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell LymphomaM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT07372352Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1, PHASE2NCT07575919Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALLLiping Dou
- ACTIVE NOT RECRUITINGPHASE1NCT07198087A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT07140016A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Astellas Pharma Global Development, Inc.
- RECRUITINGNANCT07191431A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）Ruijin Hospital
- RECRUITINGPHASE1, PHASE2NCT07018752A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasThe Lymphoma Academic Research Organisation